Clinical Trial

A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism. Previous clinical studies have demonstrated the safety of subcutaneously administered XH-02 in several patients with hypoparathyroidism and have yielded clear efficacy results. This study aims to further validate the safety and efficacy of subcutaneously injected XH-02 in the treatment of hypoparathyroidism in a expanded cohort.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-13.
Trial Details
NCT Number NCT07540286
Lead Sponsor Peking Union Medical College Hospital
Conditions Hypoparathyroidism
Enrollment 60 participants
Start Date 2026-04-13
Primary Completion 2030-04-30 (estimated)
Study Completion 2030-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-18